| |DECEMBER 20238Medtronic plc, a global leader in healthcare technology announced the signing of a final agreement to expand its collaboration with Cosmo Intelligent Medical Devices, a subsidiary of Cosmo Pharmaceuticals. This AI-driven collaboration will build on the achievements made with the GI Genius intelligent endoscopy module, providing further innovation and scalable healthcare breakthroughs for patients and caregivers worldwide.Through this exclusive global partnership, Medtronic and Cosmo Pharmaceuticals remain committed to revolutionizing endoscopy by harnessing the power of AI to improve patient outcomes. This strategic alliance reinforces Medtronic's position in AI-integrated healthcare solutions and represents a significant leap in incorporating AI into endoscopic care, as per pharmabiz.The collaboration's emphasis on cutting-edge and scalable AI platforms, such as AI Access (opens new window), exemplifies an innovative approach to healthcare and provides a wider range of diagnostic tools and treatment options. AI Access is designed to host multiple third-party AI applications to allow for faster innovation and streamlining of the AI development process across medical AI applications."Our alliance with Cosmo Pharmaceuticals is a testament to what can be achieved when two leaders in their fields unite for a common goal: transforming healthcare through AI. The GI Genius module, our first FDA-cleared AI product in gastrointestinal care, represents the initial milestone of this collaboration," said Ken Washington, chief technology officer at Medtronic. "However, the AI Access platform is where our partnership truly crystallizes our vision for healthcare transformation; it's a springboard for expanding Medtronic's AI's potential in healthcare. Our expanded partnership with Cosmo is fostering a collaborative ecosystem where Medtronic's broad spectrum of medical expertise converges with Cosmo's technological prowess, creating a synergy that propels us forward."POZydus Lifesciences Ltd signed a licensing agreement with Daewoong Pharmaceutical Co Ltd of South Korea to co-develop and commercialize a generic version of Leuprolide Acetate for depot suspension, which is used to treat advanced prostatic cancer, endometriosis, and uterine leiomyomata (fibroids). Zydus Worldwide DMCC, a wholly-owned subsidiary of Zydus Lifesciences, and Daewoong Pharmaceutical Co Ltd have entered into an exclusive licensing agreement to co-develop and commercialize Leuprolide Acetate for depot solution in six dosage strengths for the US market.Under the terms of the agreement, Zydus will assume full responsibility for the clinical development and commercialization in the US market, and Daewoong will be responsible for the pre-clinical studies, production and supply of the product, it added, as per economic times."Daewoong, utilising its proprietary technology, will produce Leuprolide Acetate for depot suspension in its manufacturing facilities located in Osong, South Korea," the filing said. The exclusive agreement also includes development, regulatory, and commercialization milestone payments contingent on success. This arrangement also includes a profit share on future sales between the two companies, according to Zydus, without providing financial details.Commenting on the agreement, Zydus Lifesciences Managing Director Sharvil Patel said, "This is an important milestone and we are happy to work with Daewoong for the generic version of Lupron Depot, empowering patients with access to a critical therapy. This is yet another step to strengthen Zydus' complex injectable portfolio."Daewoong Pharmaceutical CEO Sengho Jeon said, "Given the complexity, complex generic drug products like Lupron Depot do not exist to date, and we aim to be the first company in manufacturing the generic version of this complex, long-acting injectable Lupron Depot product." POMEDTRONIC & COSMO PHARMA WIDEN TIES TO DELIVER CONTINUED INNOVATIONZYDUS & DAEWOONG PHARMA SIGN DEAL TO DEVELOP LEUPROLIDE ACETATETOP STORIES
< Page 7 | Page 9 >